Allakos Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Allakos Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 25 Mar 2019 | Lorem |
| Allakos’ AK002 in good stead to reduce eosinophils for primary outcome success in EG and EGE, but symptom reduction of more interest for utility, experts say | 25 Mar 2019 | Manasi Vaidya |
| Allakos’ AK002 for chronic spontaneous urticaria may face conundrums designing meaningful pivotal trial after likely positive Phase IIa, experts say | 16 Jan 2019 | Arafa Salam |
| Allakos’ AK002 for chronic uriticaria had challenging study visit, Xolair-naïve enrollment criteria in its Phase IIa trial, investigators say | 17 Dec 2018 | Arafa Salam |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer